AstraZeneca Beats Q2 Profit Expectations, Holds Outlook

Note: This section contains information in English only.
Source: Dukascopy Bank SA
AstraZeneca's Q2 core earnings rose 18% to $2.63 per share, beating estimates. Strong cancer drug sales helped back its full-year 2026 growth forecast.

Actual Topics